Mixed Mullerian Cancer PDX Models

Suitable preclinical models such as patient-derived xenografts (PDX) are needed to evaluate drugs targeting mixed mullerian cancer. PDX models are known to be the most predictive preclinical model and provide an accurate approach to evaluating an agent’s efficacy prior to entering the clinic. More

PDX offer the most translational preclinical model for efficacy screening in cancer drug development. Derived directly from patient tumors and never adapted to grow in vitro, PDX models reflect the heterogeneity and diversity of the human patient population. PDX give you an accurate, predictive model of how your treatment will perform, well before entering into expensive clinical trials. CrownBio’s HuPrime® PDX models are well characterized for pathology, growth characteristics, and are also genetically/genomically annotated for gene expression, gene copy number, mutations, and fusions.
MODEL NUMBER CANCER SUBTYPE # per page
MU12499 N/ACLICK TO VIEW
MU12506 NACLICK TO VIEW
MU12527 NACLICK TO VIEW
MU12533 NECCLICK TO VIEW
MU12540 SCLCCLICK TO VIEW
MU12541 NACLICK TO VIEW
MU12554 NACLICK TO VIEW
MU12555 N/ACLICK TO VIEW
MU12561 NACLICK TO VIEW
MU12575 SCLCCLICK TO VIEW
MU12582 NACLICK TO VIEW
MU12603 NACLICK TO VIEW
MU12652 NACLICK TO VIEW
MU12659 SarcomaCLICK TO VIEW
MU12666 NACLICK TO VIEW
MU12729 SarcomaCLICK TO VIEW
MU12764 NACLICK TO VIEW
MU12778 NACLICK TO VIEW
MU12813 NACLICK TO VIEW